Gene therapy will be among the government’s priorities, a scientific official has said.
As part of its efforts to become a global hotspot for biomedical research and development, Shanghai released a cell therapy plan last year and is expected to release a gene therapy plan this year, said Zhu Qigao, deputy director of the Shanghai Science and Technology Commission.
Zhu, at the opening ceremony of the 25th Shanghai International Forum on Biotechnology and Pharmaceutical Industry, held on Tuesday afternoon, said Shanghai is climbing the ladder of biotechnology and biopharmaceutical innovation.
Last year, Shanghai approved four first-class new drugs for use and 178 others for clinical trials. Currently, several world-class laboratories and research institutes are being built in Shanghai to support the city’s development in pioneering fields such as cell processing, gene editing and synthetic biology, Zhu said.
Shanghai lists the biopharmaceutical industry as one of its three key and pioneering industries and aims to grow its market to reach a value of 1 trillion yuan ($130 billion) by the end of 2025.
This year’s forum, which runs until Thursday, includes 14 symposia on hot topics including nucleic acid drug development, challenges facing Chinese biopharmaceutical companies in expanding their global networks and cooperative development in the Yangtze River Delta region.